Calyxo closes $32 million financing round to expand kidney treatment technology
Click Here to Manage Email Alerts
Calyxo Inc. has closed $32 million in Series C financing, the company announced in a press release. The financing was led by CRG and Questa Capital; Calyxo will use the funds to evolve its kidney stone treatment solutions.
The medical device company developed the CVAC Aspiration System, which addresses the issue of providing consistent stone-free surgical outcomes. Joe Catanese, president and CEO, founded NeoTract, a minimally invasive technology that treats urinary tract symptoms. Many of NeoTract’s team members have been recruited as board members for Calyxo, according to the release.
“We are proud to invest in Calyxo and its groundbreaking kidney stone treatment technology,” Ryan Drant, founder and managing partner of Questa Capital and Calyxo board member, said in the release. “The company’s leadership team has a remarkable track record of recognizing significant unmet physician and patient needs within urology and bringing to market game-changing solutions to meet those needs. We look forward to supporting Calyxo through forthcoming development and commercialization milestones, and we are excited to see the team expand.”
Read more about
Click Here to Manage Email Alerts